https://www.fool.com/investing/2025/06/08/3-stocks-with-mouthwatering-dividends-you-can-buy/?source=iedfolrf0000001
Jun 08, 2025 -
0
fool:-6967823717339595121
0
https://www.fool.com/investing/2024/09/28/3-surprisingly-underrated-stocks-to-buy-right-now/?source=iedfolrf0000001
Sep 28, 2024 - These stocks might look like bad picks. But appearances can be deceiving.
0
fool:-7567214222034802602
0
https://www.zacks.com/stock/news/2334773/corvus-stock-up-on-initiation-of-phase-iii-lymphoma-study-on-lead-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2334773
Sep 11, 2024 - CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.
zc:2980293385066559924
0
https://www.zacks.com/stock/news/2330051/should-spdr-russell-1000-low-volatility-focus-etf-onev-be-on-your-investing-radar?cid=CS-ZC-FT-style_box_etf-2330051
Sep 02, 2024 - Style Box ETF report for ONEV
zc:3326047658427605758
0
https://www.fool.com/investing/2024/09/01/2-no-brainer-large-cap-stocks-to-buy-with-500-now/?source=iedfolrf0000001
Sep 01, 2024 - No stock is perfect, but quality businesses can stand the test of time in your portfolio.
0
fool:584923472296112572
0
https://www.zacks.com/stock/news/2329981/bristol-myers-squibb-bmy-advances-but-underperforms-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2329981
Aug 30, 2024 - Bristol Myers Squibb (BMY) closed at $49.95 in the latest trading session, marking a +0.46% move from the prior day.
zc:4616006174168704173
0
https://www.zacks.com/stock/news/2327403/should-pacer-us-cash-cows-100-etf-cowz-be-on-your-investing-radar?cid=CS-ZC-FT-style_box_etf-2327403
Aug 27, 2024 - Style Box ETF report for COWZ
zc:-7852566758599596449
0
https://www.zacks.com/stock/news/2325849/bristol-myers-bmy-hcc-combo-drug-accepted-for-fda-review?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2325849
Aug 22, 2024 - Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.
zc:-7359733387234050537
0
https://www.zacks.com/stock/news/2323426/gilead-gild-obtains-fda-approval-for-pbc-drug-livdelzi?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2323426
Aug 16, 2024 - Gilead (GILD) wins FDA nod for seladelpar for the treatment of primary biliary cholangitis (PBC) on an accelerated basis.
zc:609620447615337562
0
https://www.zacks.com/stock/news/2322722/all-you-need-to-know-about-bristol-myers-bmy-rating-upgrade-to-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2322722
Aug 15, 2024 - Bristol Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zc:633401912940070003
0